November 18, 2026
Health news, explained with evidence
LIVE

Patient-Derived Organoids Highlight Strain-Specific Potential of Engineered Bacteria in Colorectal Cancer

🔬 Research 2 min read 👁 2

Researchers at the University of California San Diego and collaborating institutions utilized patient-derived organoids to evaluate how different engineered bacterial strains interact with colorectal cancer tissue.

🔬Research

Key points

  • Patient-derived organoids help test engineered bacteria for cancer therapy.
  • Attenuated Salmonella colonized tumor organoids more efficiently than E. coli Nissle.
  • Tumor responses varied based on patient genotypes, highlighting interpatient differences.

A team of investigators has demonstrated that laboratory-grown miniature tumor models, or organoids, can effectively test how engineered bacteria target and colonize colorectal cancer tissues. Published in Nature Health Sciences, the study developed a co-culture platform pairing patient-derived colorectal cancer and matched normal mucosa organoids with two microbial strains: attenuated Salmonella typhimurium and Escherichia coli Nissle 1917. Because standard laboratory cell lines frequently fail to capture the complex architecture and genetic diversity of actual tumors, these three-dimensional organoids offer a physiologically relevant alternative for evaluating microbial cancer therapies.

The findings indicate that both bacterial strains preferentially colonize colorectal cancer organoids rather than matched healthy mucosal tissue. However, the study observed distinct differences between the microbes: attenuated Salmonella achieved substantially higher colonization efficiency and induced much stronger transcriptional and morphological changes in the host tumor cells compared to E. coli Nissle 1917. Additionally, cellular responses varied across genotypically distinct patient lines, pointing to potential interpatient variability in how tumors react to microbial treatments. Financial disclosures note that several authors hold equity or advisory roles in GenCirq Inc., a company focused on cancer therapeutics.

As an early-stage preclinical investigation utilizing laboratory organoid models, these findings remain far from clinical application. Observational and in vitro models provide valuable insights into chassis selection, but cannot guarantee safety or efficacy in human patients. Readers should consult qualified healthcare professionals regarding any personal medical decisions or ongoing clinical trials.

What to know: Patient-derived organoids may help researchers select more effective engineered bacterial strains for targeting solid tumors, though human clinical studies are still required to determine safety and real-world outcomes.

Source Nature Health Sciences — nature.com/articles/s43856-026-01992-x ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.